Does shingles arise when cell-mediated immunity declines and antibodies alone are not enough to reflect varicella-zoster virus control?

Shingles is the clinical consequence of latent varicella-zoster virus (VZV) reactivation. The evidence strongly supports declining VZV-specific cellular immunity—common with advanced age and immune dysfunction—as the principal susceptibility context, rather than antibody concentration alone.

Clinical and immune evidence

• In longitudinal cohorts of adults aged ≥60 years, VZV-specific cell-mediated immunity, particularly interferon-γ ELISPOT T-cell responses, declined with age; responses were lower at ages 70–79 than 60–69, with age the only significant associated factor.
• Prospective studies link stronger VZV-specific cellular responses to lower herpes-zoster incidence, less severe rash, and less acute/subacute pain. Conversely, autoimmune-disease populations had substantially lower IFN-γ T-cell responses than controls; subclinical reactivation was associated with lower responses and greater prednisolone exposure.
• For an 83-year-old man, age-related loss of VZV-specific cellular surveillance is therefore a clinically relevant risk context, particularly if concurrent illness or immunosuppressive treatment is present.

Mechanistic interpretation

• VZV persists latently in sensory ganglia. This intracellular reservoir is chiefly constrained by VZV-specific T-cell surveillance and effector function, including interferon-γ-producing responses.
• Immunosenescence can reduce functional T-cell responsiveness even when VZV-specific cells remain detectable. Corticosteroids and other immune dysfunction can further weaken this surveillance, allowing viral reactivation and herpes zoster.

Antibodies and practical meaning

• VZV IgG documents prior exposure or vaccine response and helps neutralize extracellular virus, but it is not a reliable standalone marker of control of latent ganglionic VZV.
• Antibody titres may persist as cellular immunity declines, and higher titres can sometimes reflect immune stimulation after reactivation rather than pre-existing protection.

Bottom line

• The claim is well supported: herpes zoster follows VZV reactivation, with aging- or immune-dysfunction-related impairment of cellular immunity being central to loss of control; antibody responses alone do not adequately represent protection against reactivation.